These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 24695752)

  • 1. Insufficient anticoagulation with dabigatran in a patient with short bowel syndrome.
    Douros A; Schlemm L; Bolbrinker J; Ebinger M; Kreutz R
    Thromb Haemost; 2014 Aug; 112(2):419-20. PubMed ID: 24695752
    [No Abstract]   [Full Text] [Related]  

  • 2. Dabigatran and acute stroke thrombolysis.
    Chong CA; Chiu L
    Cerebrovasc Dis; 2010; 30(2):202. PubMed ID: 20642027
    [No Abstract]   [Full Text] [Related]  

  • 3. Novel oral anticoagulants--key messages for the angiologist.
    Haas S; Spannagl M; Schellong SM
    Vasa; 2012 May; 41(3):177-91. PubMed ID: 22565619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New oral anticoagulants for atrial fibrillation.
    Spinler SA; Shafir V
    Circulation; 2012 Jul; 126(1):133-7. PubMed ID: 22753535
    [No Abstract]   [Full Text] [Related]  

  • 5. Dabigatran and stroke thrombolysis.
    Dempfle CE; Hennerici MG
    Cerebrovasc Dis; 2010; 30(2):203-5. PubMed ID: 20642028
    [No Abstract]   [Full Text] [Related]  

  • 6. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.
    Gong IY; Kim RB
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S24-33. PubMed ID: 23790595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The new oral anticoagulant in the Netherlands].
    Leebeek FW; Kamphuisen PW
    Ned Tijdschr Geneeskd; 2009 Apr; 153(16):773-7. PubMed ID: 19469152
    [No Abstract]   [Full Text] [Related]  

  • 8. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
    Reddy P; Giugliano RP
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of anti-Xa monitoring and differential sensitivity of prothrombin time assays: an illustrated case report.
    Than H; Loh JB; Sum CL; Ng HJ
    J Clin Pathol; 2015 Apr; 68(4):318-9. PubMed ID: 25688138
    [No Abstract]   [Full Text] [Related]  

  • 10. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new generation of oral direct anticoagulants.
    Soff GA
    Arterioscler Thromb Vasc Biol; 2012 Mar; 32(3):569-74. PubMed ID: 22345595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?
    Hellwig T; Gulseth M
    Ann Pharmacother; 2013 Nov; 47(11):1478-87. PubMed ID: 24259602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience.
    Mahaffey KW; Hellkamp AS; Patel MR; Hannan KL; Schwabe K; Nessel CC; Berkowitz SD; Halperin JL; Hankey GJ; Becker RC; Piccini JP; Breithardt G; Hacke W; Singer DE; Califf RM; Fox KA
    Circ Cardiovasc Qual Outcomes; 2013 Jul; 6(4):470-8. PubMed ID: 23759472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel oral anticoagulants: a review of the literature and considerations in special clinical situations.
    Akwaa F; Spyropoulos AC
    Hosp Pract (1995); 2013 Feb; 41(1):8-18. PubMed ID: 23466963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice.
    Huisman MV; Lip GY; Diener HC; Brueckmann M; van Ryn J; Clemens A
    Thromb Haemost; 2012 May; 107(5):838-47. PubMed ID: 22318514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New oral anticoagulants for atrial fibrillation: a neurologist's view].
    van Dijk EJ; Koudstaal PJ; Roos YB; Brouwers PJ; Kappelle LJ
    Ned Tijdschr Geneeskd; 2012; 156(39):A5283. PubMed ID: 23009824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dabigatran may not be an effective anticoagulant for haemodialysis.
    Cho Y; Mills K; Sturtevant JM; Pillans PI; Mudge DW
    Nephrology (Carlton); 2010 Aug; 15(5):594-5. PubMed ID: 20649885
    [No Abstract]   [Full Text] [Related]  

  • 18. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
    Providência R; Marijon E; Albenque JP; Combes S; Combes N; Jourda F; Hireche H; Morais J; Boveda S
    Europace; 2014 Aug; 16(8):1137-44. PubMed ID: 24550347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New anticoagulant drugs among elderly patients is caution necessary?: Comment on "The use of dabigatran in elderly patients".
    Jacobs JM; Stessman J
    Arch Intern Med; 2011 Jul; 171(14):1287-8. PubMed ID: 21788546
    [No Abstract]   [Full Text] [Related]  

  • 20. [Anticoagulation in atrial fibrillation: a new era has begun].
    Moser M; Bode C
    Hamostaseologie; 2012; 32(1):37-9. PubMed ID: 22124808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.